This study shows that the ORR of IPCGOR combined with IL-2 treatment for advanced NSCLC is 67.4%, and the DCR is 97.4%, with mPFS of 8.5 months, respectively. This evidence concerns the gene IL2 and non-small cell lung carcinoma.